Barcelona. Prous Institute for Biomedical Research
is proud to announce the nomination call for the 2016 Prous
Institute-Overton and Meyer Award for New Technologies in Drug
Discovery. Following their tradition of drug discovery science and
technology, Prous Institute has donated the award biennially since 2004,
acknowledging outstanding achievements in the field of medicinal
chemistry. Next year’s award will be given at the XXIV EFMC “International Symposium on Medicinal Chemistry”
(EFMC-ISMC) to be held in Manchester, UK from August 28 to September 1,
2016. The deadline for nominations is January 31, 2016.
About the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
The award was established to encourage innovation and investigation
in technologies related to drug discovery. It consists of a monetary
prize, a diploma, and an invitation to give a lecture at the upcoming
EFMC-ISMC International Symposium on Medicinal Chemistry.
The requirements for a nomination for the Prous Institute-Overton and
Meyer Award, are: a nomination letter, a brief CV including a list of
selected publications and two supporting letters. Self-nominations are
also accepted. The nominations should be submitted to Prof. Koen
Augustyns, President of the EFMC, via this link. More information is available here.
About Prous Institute for Biomedical Research
Prous Institute for Biomedical Research is a privately-held research
organization created in order to put into practice innovative in silico
approaches to accelerate drug discovery. It was founded as a spin-off of
Prous Science, the leading scientific information provider (creator of
brands such as Integrity, MDDR, Drugs of the Future, Drug Data Report,
Drugs of Today, Drug News and Perspectives, Methods and Findings in
Experimental and Clinical Pharmacology and Timely Topics in Medicine)
acquired by Thomson Reuters in 2007. Building on over 50 years of
experience creating and managing biomedical knowledge, Prous Institute
for Biomedical Research has developed Symmetry, an innovative predictive
analytics platform to elucidate the efficacy and safety profile of new
molecular entities. The platform helps to de-risk and prioritize
projects and assays and speed up drug discovery and development,
reducing time, costs and attrition rates. Symmetry applies advanced
machine learning techniques to a variety of structural features and
physicochemical properties of small molecules to provide quality
predictions of biological effects.
For more information, please contact Prous Institute.